|
The demand for biosimilars product is usually high in countries, where generics have been approved by the government and usage rate of the same is extremely high. Most of the developing countries have generic approvals due to which they represent the biggest market for the biosimilars products. Hence, Asia Pacific was estimated to account for around 35% of the global biosimilars industry at the end of 2009, says our new research report “Asia Pacific Biotechnology Market (2008-2012)”.
Our team of experts has also found that most of the countries of Asian origin, such as India, China, South Korea, etc. are at the developing stage and provide a huge customer base for the companies, on account of which the Asia Pacific region has acquired such a huge share of the market. Besides, these countries have generics approval from many years, which has further fuelled the growth of the market.
Our research report has covered various countries of the region on the basis of developments taking place in various countries. The countries, which have been covered in the report, are Japan, China, South Korea, India, Australia, Taiwan, Malaysia, New Zealand, and Singapore. Most importantly, for each of the country covered in the report, detail description of government regulations and key players dominating the market has been included in the report.
Our report “Asia Pacific Biotechnology Market (2008-2012)” provides thorough analysis of the various segments of the biotech industry, like biopharma, bioservices, bioagriculture, industrial biotechnology, and bioinformatics together with the detail study of the investments opportunities in various countries of the region. The report has thoroughly examined current market trends, industrial developments, and competitive landscape to enable clients understands the market structure and its progress in coming years. Due consideration has been given to the possible after effects of recession on the industry. It will help clients to have a proper insight of the current and future outlook of the Asia Pacific biotech market.
For more information visit: http://www.rncos.com/Report/IM138.htm |
